Revance Therapeutics (RVNC) Received its Third Buy in a Row
After Mizuho Securities and Needham gave Revance Therapeutics (NASDAQ: RVNC) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Douglas Tsao reiterated a Buy rating on Revance Therapeutics today and set a price target of $23.00. The company’s shares closed last Monday at $15.07.
According to TipRanks.com, Tsao is a 1-star analyst with an average return of -1.8% and a 46.3% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Minerva Neurosciences, Amag Pharmaceuticals, and Theravance Biopharma.
Currently, the analyst consensus on Revance Therapeutics is a Strong Buy with an average price target of $32.33, implying an 113.8% upside from current levels. In a report issued on October 30, Wells Fargo also upgraded the stock to Buy with a $20.00 price target.
See today’s analyst top recommended stocks >>
Based on Revance Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $41.41 million. In comparison, last year the company had a GAAP net loss of $32.83 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Revance Therapeutics, Inc. is a clinical stage biotechnology company. It is engaged in the development, manufacturing, and commercialization of novel botulinum toxin products for multiple aesthetic, and therapeutic applications.
Read More on RVNC: